Retinitis pigmentosa 79

disease
On this page

Also known as RP79

Summary

Retinitis pigmentosa 79 (MONDO:0044320) is a disease caused by HK1 (GenCC Strong), with 2 cohort genes.

At a glance

  • Causal gene: HK1 (GenCC Strong)
  • Cohort genes: 2
  • ClinVar variants: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameretinitis pigmentosa 79
Mondo IDMONDO:0044320
OMIM617460
DOIDDOID:0061108
UMLSC4479526
MedGen1386200
GARD0016231
Is cancer (heuristic)no

Also known as: retinitis pigmentosa 79 · RP79

Data availability: 17 ClinVar variants · 4 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinal degenerationinherited retinal dystrophyretinitis pigmentosaretinitis pigmentosa 79

Related subtypes (101): retinitis pigmentosa 6, cone-rod dystrophy 2, retinitis pigmentosa 1, retinitis pigmentosa 9, retinitis pigmentosa 10, dominant pericentral pigmentary retinopathy, late-adult onset retinitis pigmentosa, autosomal recessive pericentral pigmentary retinopathy, retinitis pigmentosa 3, retinitis pigmentosa 24, retinitis pigmentosa 23, retinitis pigmentosa 34, retinitis pigmentosa 2, retinitis pigmentosa Y-linked, retinitis pigmentosa 13, retinitis pigmentosa 12, retinitis pigmentosa 14, retinitis pigmentosa 11, retinitis pigmentosa 17, retinitis pigmentosa 18, retinitis pigmentosa 19, retinitis pigmentosa 22, retinitis pigmentosa 25, retinitis pigmentosa 28, retinitis pigmentosa 30, retinitis pigmentosa 7, retinitis pigmentosa 26, retinitis pigmentosa 32, retinitis pigmentosa 31, retinitis pigmentosa 35, retinitis pigmentosa 33, retinitis pigmentosa 36, retinitis pigmentosa 37, retinitis pigmentosa 41, retinitis pigmentosa 29, retinitis pigmentosa 46, retinitis pigmentosa 42, retinitis pigmentosa 50, retinitis pigmentosa 54, retinitis pigmentosa 51, retinitis pigmentosa 55, retinitis pigmentosa 56, retinitis pigmentosa 57, retinitis pigmentosa 58, cone-rod dystrophy 15, retinitis pigmentosa 4, retinitis pigmentosa 27, retinitis pigmentosa 49, retinitis pigmentosa 47, retinitis pigmentosa 45, retinitis pigmentosa 44, retinitis pigmentosa 20, retinitis pigmentosa 40, retinitis pigmentosa 39, retinitis pigmentosa 43, retinitis pigmentosa 48, retinitis pigmentosa 59, retinitis pigmentosa 38, retinitis pigmentosa 60, retinitis pigmentosa 61, retinitis pigmentosa 62, retinitis pigmentosa 63, cone-rod dystrophy 16, retinitis pigmentosa 66, retinitis pigmentosa with or without situs inversus, retinitis pigmentosa 67, retinitis pigmentosa 68, retinitis pigmentosa 69, retinitis pigmentosa 70, retinal dystrophy and obesity, retinitis pigmentosa 71, retinitis pigmentosa 72, retinitis pigmentosa 73, retinitis pigmentosa 74, retinitis pigmentosa 75, retinitis pigmentosa 76, retinitis pigmentosa 77, retinitis pigmentosa 92, retinitis pigmentosa 93, retinitis pigmentosa 83, retinitis pigmentosa 84, retinitis pigmentosa 85, retinitis pigmentosa 86, retinitis pigmentosa 87 with choroidal involvement, retinitis pigmentosa 88, retinitis pigmentosa 90, retinitis pigmentosa 81, retinitis pigmentosa 78, retinitis pigmentosa 80, retinitis pigmentosa 94, variable age at onset, retinitis pigmentosa 53, retinitis pigmentosa 65, retinitis pigmentosa 64, retinitis pigmentosa 95, retinitis pigmentosa 96, retinitis pigmentosa 97, retinitis pigmentosa 98, retinitis pigmentosa 99, retinitis pigmentosa 100, retinitis pigmentosa 101, retinitis pigmentosa 7, digenic

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

17 retrieved; paginated sample, class counts are floors:

6 benign, 4 uncertain significance, 4 pathogenic/likely pathogenic, 2 benign/likely benign, 1 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
1700095NM_000188.3(HK1):c.1240G>A (p.Gly414Arg)HK1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
372693NM_000188.3(HK1):c.1370C>T (p.Thr457Met)HK1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
421007NM_000188.3(HK1):c.1334C>T (p.Ser445Leu)HK1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
424845NM_000188.3(HK1):c.2539G>A (p.Glu847Lys)HK1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2581721NM_000188.3(HK1):c.613del (p.Ala205fs)HK1Likely pathogenicno assertion criteria provided
1333598NM_000188.3(HK1):c.1525G>A (p.Val509Ile)HK1Uncertain significancecriteria provided, single submitter
1687570NM_000188.3(HK1):c.1298G>A (p.Arg433His)HK1Uncertain significancecriteria provided, multiple submitters, no conflicts
971751NM_000188.3(HK1):c.1550G>A (p.Arg517Gln)HK1Uncertain significancecriteria provided, multiple submitters, no conflicts
994250NM_000188.3(HK1):c.949G>A (p.Gly317Ser)HK1Uncertain significancecriteria provided, multiple submitters, no conflicts
1285347NM_001358263.1(HK1):c.75+23T>CHK1Benigncriteria provided, multiple submitters, no conflicts
1285348NM_000188.3(HK1):c.1839+31G>AHK1Benigncriteria provided, multiple submitters, no conflicts
1285349NM_000188.3(HK1):c.2219+27T>CHK1Benigncriteria provided, multiple submitters, no conflicts
255483NM_000188.3(HK1):c.1443G>A (p.Lys481=)HK1Benigncriteria provided, multiple submitters, no conflicts
439787NM_000188.3(HK1):c.78C>G (p.Leu26=)HK1Benigncriteria provided, multiple submitters, no conflicts
776515NM_000188.3(HK1):c.1031+6T>CHK1Benign/Likely benigncriteria provided, multiple submitters, no conflicts
994062NM_001358263.1(HK1):c.75+5174A>GHK1Benigncriteria provided, multiple submitters, no conflicts
994196NM_001358263.1(HK1):c.53T>C (p.Leu18Pro)HK1Benign/Likely benigncriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 35 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
HK1StrongAutosomal dominantretinitis pigmentosa 7916
KCNA4StrongAutosomal dominantretinitis pigmentosa 7919

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
HK1Orphanet:90031Non-spherocytic hemolytic anemia due to hexokinase deficiency
HK1Orphanet:99953Charcot-Marie-Tooth disease type 4G

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence2

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
HK1HGNC:4922ENSG00000156515P19367Hexokinase-1gencc,clinvar
KCNA4HGNC:6222ENSG00000182255P22459Potassium voltage-gated channel subfamily A member 4gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
HK1Hexokinase-1Catalyzes the phosphorylation of various hexoses, such as D-glucose, D-glucosamine, D-fructose, D-mannose and 2-deoxy-D-glucose, to hexose 6-phosphate (D-glucose 6-phosphate, D-glucosamine 6-phosphate, D-fructose 6-phosphate, D-mannose 6-p…
KCNA4Potassium voltage-gated channel subfamily A member 4Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Ion channel155.8×0.036
Kinase113.9×0.071

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
HK1Kinaseyes2.7.1.1Hexokinase, Hexokinase_BS, Hexokinase_N
KCNA4Ion channelyesBTB/POZ_dom, T1-type_BTB, K_chnl_volt-dep_Kv

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)2
unknown0

Top tissues across cohort

TissueCohort genes
cerebellar vermis1
pharyngeal mucosa1
pons1
adrenal tissue1
nucleus accumbens1
secondary oocyte1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
HK1291ubiquitousmarkercerebellar vermis, pharyngeal mucosa, pons
KCNA4142broadmarkeradrenal tissue, nucleus accumbens, secondary oocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
KCNA42,311
HK12,298

Structural data

PDB: 1 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
HK1P1936710

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
KCNA4P2245970.48

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 6. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Defective HK1 causes hexokinase deficiency (HK deficiency)15710.0×0.001HK1
Synthesis of GDP-mannose1951.7×0.003HK1
Glycolysis1142.8×0.012HK1
Voltage gated Potassium channels1121.5×0.012KCNA4
Potassium Channels167.2×0.018KCNA4
Neuronal System122.1×0.045KCNA4

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
obsolete GDP-mannose biosynthetic process from mannose12808.7×0.003HK1
GDP-mannose biosynthetic process11404.3×0.003HK1
obsolete establishment of protein localization to mitochondrion11404.3×0.003HK1
maintenance of protein location in mitochondrion11404.3×0.003HK1
mannose metabolic process11053.2×0.003HK1
carbohydrate phosphorylation11053.2×0.003HK1
glucose 6-phosphate metabolic process1648.1×0.004HK1
fructose 6-phosphate metabolic process1561.7×0.004HK1
positive regulation of cytokine production involved in immune response1495.6×0.004HK1
canonical glycolysis1351.1×0.006HK1
intracellular glucose homeostasis1290.6×0.006HK1
glycolytic process1191.5×0.009HK1
action potential1179.3×0.009KCNA4
positive regulation of interleukin-1 beta production1129.6×0.010HK1
glucose metabolic process1127.7×0.010HK1
potassium ion transport195.8×0.013KCNA4
potassium ion transmembrane transport168.0×0.017KCNA4
protein homooligomerization161.1×0.018KCNA4
inflammatory response118.9×0.055HK1
innate immune response116.8×0.059HK1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
HK113
KCNA400

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
EBSELEN3HK1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
KCNA430Binding:26, ADMET:2, Toxicity:1, Functional:1
HK112Binding:9, Functional:3

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
HK12.7.1.1hexokinase

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
EBSELEN3HK1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved1HK1
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug1KCNA4
EDifficult family or no structure, no drug0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
KCNA430

Clinical trials & evidence

Clinical trials

Clinical trials: 0.